Daurismo (Glasdegib Maleate) Patent Expiration, LOE Window & CMS Spending

Daurismo (Glasdegib Maleate) by Pfizer: FDA Orange Book core substance LOE 2036-04-13, 0 AB generics, $3.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN210656 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-04-13
Last Listed Patent or Exclusivity Date2036-04-13
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.7M
2024 Medicare Part D Spend$3.7M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.